Ocular Excipient Market

Ocular Excipient Market Outlook (2024 to 2034)

Revenue from the global ocular excipient market is analyzed to reach US$ 900 million in 2024 and touch a value of US$ 2.13 billion by the end of 2034. This latest research study by skilled analysts at Fact.MR states that worldwide demand is projected to rise at a CAGR of 9% between 2024 and 2034.

The market for ocular excipients is significantly influenced by the rising prevalence of eye conditions, such as age-related macular degeneration (AMD), glaucoma, cataracts, and dry eye syndrome. This increasing load is caused by several factors, including aging populations, extended screen time, environmental stressors, and others, all of which call for efficient ocular treatments.

Drug retention, bioavailability, and controlled release are enhanced by advancements in ocular drug delivery technologies, including hydrogels, nano-formulations, and microspheres. Excipients that guarantee stability, solubility, and compatibility with ocular tissues are crucial to these developments.

The requirement for non-irritating and biocompatible excipients to improve the efficacy and safety of ocular formulations is growing. Because of their ability to moisturize, stabilize, and produce films, excipients, such as hyaluronic acid, carboxymethyl cellulose, and polyethylene glycols (PEGs) are widely included in ophthalmic products.

North America is estimated to hold 36.9% of the worldwide market share in 2024 because of the high prevalence of eye illnesses, substantial R&D expenditures, and well-established healthcare infrastructure. The need for advanced and new ophthalmic medication formulations is driven by the aging population as well as the rise in glaucoma and dry eye syndrome patients.

Based on product type, the demand for diluents is projected to reach US$ 386.4 million in 2024 due to their vital function in improving the stability, solubility, and bioavailability of ophthalmic medications. By lowering concentration variability and enhancing formulation consistency, diluents are crucial for precise drug administration, particularly in liquid and semi-solid treatments, such as ointments and eye drops.

Smoothening of FDA approval processes has been crucial for this market as novel excipients with improved functionalities are easily approved and used for better formulation without being stuck in the legal web.

What is driving the demand for the Ocular Excipients Market?

Excipients are an important part of the drug development process and ensure that the formulation remains stable throughout the development process as well as when it is administered. It is basically any other component of the drug outside the medicinal component as it acts as a vehicle or a carrier for the medicinal product.

This way stability to the formulation is provided. The wrong selection of excipients leads to complications, such as intoxication of the patients. In ocular drugs, they play an important role in maintaining the tonicity, pH, stability, viscosity, and sterility of the formulation.

Novel systems for drug delivery are invented on a very large scale and this is driving the excipients market, as certain advanced forms are required to put certain specific properties into the formulation. In this case, a single excipient is required to perform several functionalities to make the formulation versatile and novel. This factor will ultimately improve the overall performance of the drug, which will finally lead to financial gains in the market.

Another major driver that emerges is that of new excipients, which will change the landscape of disease treatment the characteristic of this component is to prove effective in multiple ways in a formulation of the drug where they play diverse roles in ensuring the effectiveness of the drug which their earlier counterparts didn’t.

The pharmaceutical landscape is changing very rapidly and due to the emergence of new diseases, the research has gained pace. This in turn demands the development of improved drugs; for which some of the previously used excipients might not be suitable. This has boosted the manufacturers in searching for new excipients, which are more suitable with their versatile capabilities.

The main issue with ocular drug delivery is its very poor bioavailability due to the rapid washout of the drug. This results in low permeation through the membranes.

A 15 April 2021, study published in the International Journal of Pharmaceutics analysed muco-adhesiveness and permeation capability of a new excipient known as thiolated cyclodextrins. Improvement in permeation in the conjunctiva, sclera, as well as cornea, was seen. This also unlatches a new pathway into using thiolated cyclodextrins as an excipient in many more drug formulations in the future.

Newly Emerged Excipients with an Application in the Ocular Market

Ocular drug delivery has been mostly limited to injections and topical applications. The most widely used topical application has proven to be a convenient method despite it failing to maintain an effective level of concentration of the drug at the target site for the ideal time period.

The 2021 review article from MDPI has collectively put up the latest advances in the excipients market, which have the potential in improving the bioavailability of ocular drugs. Chitosan, hyaluronic acid, poloxamers, and gelatin are a few noteworthy that have displayed a promising potential in limiting the limitations presented by previous ocular delivery systems.

The US and Canada Excipient Market

The healthcare system of the U.S. is well known for its advanced infrastructure and expenditure. Various regulatory rules and insurance policies are adopted to control the healthcare regime of the country. The US doesn’t have a specific regulation when it comes to pharmaceutical excipients as long as they fit the mechanisms of approval set by the US FDA. This is sure to boost the acceptance of novel excipients in the US and make it the most lucrative market.

Europe Ocular Excipients Market

Europe is the second major market in this field as efforts are made by the International Pharmaceutical Excipients Commission about getting the necessary approvals and recognitions from the European Union with respect to the evolving excipient market.

At the IPEC Europe Excipient Forum of 2018, it was updated that excipients, which have improved functionalities in comparison to the regular blends were not clearly defined in the European Union, despite them being marketed as one for many years. It was then decided that a draft is to be sent to the EU Commission with specific quality control measures required for these Co-processed excipients or CPEs for a review.

Who are the key manufacturing supplying companies in the Ocular Excipients market?

Key manufacturers and suppliers:

• Anton Paar
• BASF
• Beneo
• Evonik
• EXCi PACT
• Fuji Chemical Industries USA, Inc.
• InVitria
• Innophos
• JRS Pharma
• IOI Oleochemical
• Millipore Sigma
• Mallinckrodt Pharmaceuticals
• Pfanstiehl
• Perkin Elmer
• Natoli
• DFE Pharma

Ocular Excipient Market Report Highlights:

• Detailed overview of the parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current, and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint